Mumbai, July 1 -- Morepen Laboratories today issued an update on its recently announced Rs 825 crore CDMO mandate. The first commercial dispatch, valued at approximately Rs 50 crore, has already been completed by the company under the program during Q1FY2026-27. This marks the successful transition of the mandate from validation and qualification stage to commercial execution stage.

Published by HT Digital Content Services with permission from Capital Market....